Bio-Techne (TECH) Non Operating Investment Income (2022 - 2023)
Bio-Techne's quarterly Non Operating Investment Income came in at $283000.0 in Q3 2023, down 99.43% year-on-year from $49.8 million in Q3 2022, and up 141.56% quarter-over-quarter from -$681000.0 in Q2 2023.
Bio-Techne has reported Non Operating Investment Income for 2 years, with the latest figure at $283000.0 in Q3 2023.
- For the quarter ending Q3 2023, Non Operating Investment Income fell 99.43% year-over-year to $283000.0; the trailing twelve-month figure through Jun 2024 stood at $283000.0 (down 99.43% YoY), and the FY2024 full-year result was $283000.0, down 99.43% from the prior year.
- Non Operating Investment Income for Q3 2023 stood at $283000.0, up from -$681000.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $49.8 million in Q3 2022, with the low at -$681000.0 in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 230,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Bio-Techne | 7.92 Bn | 7.71 Bn | 208.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 283,000.00 |
| Sep 30, 2023 | 283,000.00 |
| Jun 30, 2023 | -681,000.00 |
| Jun 30, 2023 | -681,000.00 |
| Mar 31, 2023 | 314,000.00 |
| Mar 31, 2023 | 314,000.00 |
| Dec 31, 2022 | -74,000.00 |
| Dec 31, 2022 | -74,000.00 |
| Sep 30, 2022 | 49.77 Mn |
| Sep 30, 2022 | 49.77 Mn |